Aurora Private Wealth Inc. Sells 115 Shares of Eli Lilly and Company $LLY

Aurora Private Wealth Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 20.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 442 shares of the company’s stock after selling 115 shares during the quarter. Aurora Private Wealth Inc.’s holdings in Eli Lilly and Company were worth $344,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LLY. Brighton Jones LLC grew its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after buying an additional 1,730 shares during the period. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd increased its holdings in Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company’s stock worth $352,000 after acquiring an additional 85 shares in the last quarter. GAMMA Investing LLC increased its holdings in Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company’s stock worth $14,866,000 after acquiring an additional 3,696 shares in the last quarter. Finally, Arvest Investments Inc. increased its holdings in Eli Lilly and Company by 19.9% in the 1st quarter. Arvest Investments Inc. now owns 1,085 shares of the company’s stock worth $896,000 after acquiring an additional 180 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, Director J Erik Fyrwald acquired 1,565 shares of the company’s stock in a transaction on Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jamere Jackson acquired 200 shares of the company’s stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 over the last three months. Corporate insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. JPMorgan Chase & Co. cut their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a report on Tuesday, September 16th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Daiwa Capital Markets downgraded Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price for the company. in a research report on Sunday, August 17th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research report on Wednesday. Finally, HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $948.56.

Eli Lilly and Company Stock Down 2.6%

NYSE LLY opened at $833.08 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. The company has a fifty day moving average of $742.42 and a two-hundred day moving average of $766.36. The firm has a market capitalization of $788.47 billion, a price-to-earnings ratio of 54.45, a PEG ratio of 1.19 and a beta of 0.47. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.